China Threat Triggers Potential Mining Boom for Investors

China has almost a 90% lock on critical minerals needed to produce our military, mobile, and green technologies. Mining companies are scrambling to find domestic sources to break China's chokehold on supply chains. Nevada, Idaho and Montana are key to securing a domestic supply.

Discover the one company set to break China's grip

BMRN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.75%

Insider Buying (Last 12 Months): $314,468.75

Insider Selling (Last 12 Months): $16,349,524.92

BioMarin Pharmaceutical Insider Trading History Chart

BioMarin Pharmaceutical Share Price & Price History

^$103.53

▼ -2.03 (-1.92%)

As of 12/5/2022 05:19 PM ET

Days: 30 | 90 | 365

Are Investors Returning to the Small-Cap Uranium Sector?

From Investing Trends | Ad

Back in the early 2000's, small-cap Paladin Energy was the darling of the last uranium boom when it shot up from ten cents to over nine dollars.

Today's uranium supply/demand imbalance has a lot in common with the last market cycle. Combined with the energy crisis and "green revolution," this could be setting the stage for the next uranium boom.

Get the Full Story on Uranium Opportunities Here

BioMarin Pharmaceutical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/23/2022	Brian R. Mueller	CFO	Sell	5,379	$98.73	$531,068.67	28,847
11/2/2022	Jeffrey Robert Ajer	EVP	Sell	3,000	$86.12	$258,360.00	41,088
10/31/2022	Jean Jacques Bienaime	CEO	Sell	1,500	$86.55	$129,825.00	322,824
10/31/2022	Mark J Alles	Director	Buy	3,625	$86.75	$314,468.75	10,905
10/14/2022	Jean Jacques Bienaime	CEO	Sell	4,000	$89.89	$359,560.00	324,324
8/15/2022	Jean Jacques Bienaime	CEO	Sell	3,000	$95.21	$285,630.00	328,324
8/12/2022	Jean Jacques Bienaime	CEO	Sell	4,000	$94.75	$379,000.00	331,324
8/11/2022	Jeffrey Robert Ajer	EVP	Sell	3,000	$95.62	$286,860.00	44,088
8/8/2022	Charles Greg Guyer	EVP	Sell	6,205	$96.56	$599,154.80	42,168
7/8/2022	Brian R. Mueller	CFO	Sell	7,337	$89.50	$656,661.50	30,726
7/8/2022	George Eric Davis	EVP	Sell	7,398	$90.00	$665,820.00	58,941
5/26/2022	Jeffrey Robert Ajer	EVP	Sell	1,308	$78.94	$103,253.52	54,109
5/5/2022	Jean Jacques Bienaime	CEO	Sell	10,000	$84.14	$841,400.00	335,324
5/4/2022	Brian R. Mueller	CFO	Sell	11,800	$84.50	$997,100.00	38,639
5/2/2022	George Eric Davis	EVP	Sell	15,347	$80.38	$1,233,591.86	66,339
5/2/2022	Richard A. Meier	Director	Sell	3,878	$82.09	$318,345.02	104,014
4/28/2022	Jean Jacques Bienaime	CEO	Sell	20,000	$83.79	$1,675,800.00	334,983
4/18/2022	Jean Jacques Bienaime	CEO	Sell	20,000	$81.91	$1,638,200.00	334,983
4/14/2022	Jean Jacques Bienaime	CEO	Sell	10,000	$83.66	$836,600.00	334,983
4/14/2022	V. Bryan Lawlis	Director	Sell	4,250	$83.66	$355,555.00	23,970
4/13/2022	Jeffrey Robert Ajer	EVP	Sell	1,180	$82.47	$97,314.60	55,077
3/29/2022	Jeffrey Robert Ajer	EVP	Sell	1,618	$79.43	$128,517.74
3/23/2022	Jeffrey Robert Ajer	EVP	Sell	6,129	$81.78	$501,229.62
3/21/2022	George Eric Davis	EVP	Sell	6,129	$81.29	$498,226.41
3/10/2022	Jean Jacques Bienaime	CEO	Sell	15,000	$77.57	$1,163,550.00
2/28/2022	Dennis Slamon	Director	Sell	6,396	$78.33	$500,998.68
1/14/2022	V. Bryan Lawlis	Director	Sell	4,250	$87.61	$372,342.50
1/13/2022	Jean Jacques Bienaime	CEO	Sell	5,000	$87.86	$439,300.00
12/15/2021	Jean Jacques Bienaime	CEO	Sell	6,000	$82.71	$496,260.00
12/1/2021	Jean Jacques Bienaime	CEO	Sell	1,500	$87.22	$130,830.00
10/26/2021	Jeffrey Robert Ajer	EVP	Sell	2,739	$73.60	$201,590.40
5/10/2021	Jean Jacques Bienaime	CEO	Sell	8,513	$77.29	$657,969.77	312,352
5/7/2021	Brian R. Mueller	CFO	Sell	6,709	$79.50	$533,365.50	31,357
5/7/2021	Jean Jacques Bienaime	CEO	Sell	25,000	$78.12	$1,953,000.00	303,839
5/6/2021	Richard A. Meier	Director	Sell	5,068	$78.38	$397,229.84	99,340
5/3/2021	George Eric Davis	EVP	Sell	4,673	$78.30	$365,895.90	68,781
4/23/2021	Jean Jacques Bienaime	CEO	Sell	10,000	$79.34	$793,400.00	312,498
4/19/2021	George Eric Davis	EVP	Sell	2,709	$79.58	$215,582.22	71,149
4/8/2021	Jeffrey Robert Ajer	EVP	Sell	1,537	$78.81	$121,130.97	58,250
4/1/2021	Brian R. Mueller	CFO	Sell	5,692	$76.30	$434,299.60	31,016
3/24/2021	Jeffrey Robert Ajer	EVP	Sell	1,181	$76.30	$90,110.30	61,439
3/18/2021	Jeffrey Robert Ajer	EVP	Sell	1,308	$77.99	$102,010.92	64,133
3/11/2021	Jean Jacques Bienaime	CEO	Sell	7,000	$77.68	$543,760.00	295,652
3/5/2021	Michael G. Grey	Director	Sell	5,000	$76.28	$381,400.00	47,840
2/19/2021	Jean Jacques Bienaime	CEO	Sell	7,000	$83.58	$585,060.00	302,552
2/17/2021	Jean Jacques Bienaime	CEO	Sell	8,000	$84.54	$676,320.00	303,552
1/29/2021	Jean Jacques Bienaime	CEO	Sell	8,334	$82.67	$688,971.78	303,885
1/27/2021	Jean Jacques Bienaime	CEO	Sell	8,333	$85.49	$712,388.17	303,885
12/28/2020	Jean Jacques Bienaime	CEO	Sell	1,500	$88.77	$133,155.00	297,052
10/14/2020	Jeffrey Robert Ajer	EVP	Sell	2,121	$79.91	$169,489.11	61,281
8/31/2020	David E.I. Pyott	Director	Buy	12,800	$78.26	$1,001,728.00	29,840
8/3/2020	Michael G. Grey	Director	Sell	2,500	$120.35	$300,875.00	45,340
7/20/2020	Henry J. Fuchs	Insider	Sell	126,389	$130.00	$16,430,570.00	104,245
7/13/2020	Henry J. Fuchs	Insider	Sell	23,011	$130.00	$2,991,430.00	102,995
6/26/2020	Willard H. Dere	Director	Sell	4,430	$123.61	$547,592.30	13,290
6/19/2020	Jeffrey Robert Ajer	EVP	Sell	15,000	$124.00	$1,860,000.00	63,402
6/5/2020	V. Bryan Lawlis	Director	Sell	4,430	$107.46	$476,047.80	18,850
5/8/2020	Jean Jacques Bienaime	CEO	Sell	20,000	$91.72	$1,834,400.00	318,552
5/4/2020	Jean Jacques Bienaime	CEO	Sell	5,000	$88.00	$440,000.00	298,552
5/1/2020	George Eric Davis	EVP	Sell	12,504	$89.38	$1,117,607.52	78,181
5/1/2020	Jean Jacques Bienaime	CEO	Sell	4,000	$89.38	$357,520.00	298,552
4/28/2020	Jean Jacques Bienaime	CEO	Sell	20,000	$97.58	$1,951,600.00	318,213
4/24/2020	Henry J. Fuchs	Insider	Sell	20,000	$95.88	$1,917,600.00	109,014
4/20/2020	Henry J. Fuchs	Insider	Sell	17,213	$90.00	$1,549,170.00	122,656
4/9/2020	Jean Jacques Bienaime	CEO	Sell	10,000	$79.06	$790,600.00	308,213
4/8/2020	Jeffrey Robert Ajer	EVP	Sell	2,407	$79.98	$192,511.86	63,064
4/1/2020	Jeffrey Robert Ajer	EVP	Sell	1,537	$82.00	$126,034.00	65,471
3/24/2020	Jeffrey Robert Ajer	EVP	Sell	2,041	$74.36	$151,768.76	68,626
3/17/2020	V. Bryan Lawlis	Director	Sell	3,750	$75.39	$282,712.50	18,980
3/9/2020	Jean Jacques Bienaime	CEO	Sell	10,000	$89.52	$895,200.00	296,443
1/14/2020	Jean Jacques Bienaime	CEO	Sell	8,000	$87.95	$703,600.00	335,530
1/7/2020	Jean Jacques Bienaime	CEO	Sell	3,000	$84.46	$253,380.00	330,530
12/27/2019	Jean Jacques Bienaime	CEO	Sell	5,000	$86.16	$430,800.00
12/17/2019	V. Bryan Lawlis	Director	Sell	3,750	$83.36	$312,600.00	27,340

Are Investors Returning to the Small-Cap Uranium Sector?

From Investing Trends | Ad

Get the Full Story on Uranium Opportunities Here

SEC Filings (Institutional Ownership Changes) for BioMarin Pharmaceutical (NASDAQ:BMRN)

94.84% of BioMarin Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

BioMarin Pharmaceutical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/1/2022	Robeco Institutional Asset Management B.V.	57,534	$4.88M	0.0%	+7.2%	0.031%
11/23/2022	Toroso Investments LLC	5,051	$0.43M	0.0%	+6.0%	0.003%
11/22/2022	Mint Tower Capital Management B.V.	16,000	$1.36M	0.1%	N/A	0.009%
11/22/2022	Teachers Retirement System of The State of Kentucky	139,471	$11.82M	0.1%	N/A	0.075%
11/21/2022	California State Teachers Retirement System	301,146	$25.53M	0.0%	-0.9%	0.162%
11/18/2022	Industrial Alliance Investment Management Inc.	47,060	$3.99M	0.1%	+4.5%	0.025%
11/18/2022	National Pension Service	279,423	$23.77M	0.0%	-9.4%	0.151%
11/17/2022	M&T Bank Corp	6,518	$0.55M	0.0%	-3.6%	0.004%
11/16/2022	Alpha Paradigm Partners LLC	17,850	$1.51M	0.7%	N/A	0.010%
11/16/2022	Balyasny Asset Management LLC	785,788	$66.61M	0.2%	+39.2%	0.424%
11/16/2022	CIBC Private Wealth Group LLC	57,162	$4.85M	0.0%	-8.2%	0.031%
11/16/2022	Fred Alger Management LLC	38,686	$3.28M	0.0%	-45.8%	0.021%
11/16/2022	Meiji Yasuda Asset Management Co Ltd.	15,431	$1.31M	0.1%	+11.6%	0.008%
11/16/2022	Meiji Yasuda Life Insurance Co	7,797	$0.66M	0.0%	+97.9%	0.004%
11/16/2022	Tamarack Advisers LP	71,000	$6.02M	3.5%	+136.7%	0.038%
11/15/2022	Nomura Holdings Inc.	200,653	$17M	0.1%	+356.0%	0.108%
11/15/2022	Neuberger Berman Group LLC	166,837	$14.14M	0.0%	+507.1%	0.090%
11/15/2022	Alliancebernstein L.P.	92,167	$7.81M	0.0%	-59.9%	0.050%
11/15/2022	Public Employees Retirement System of Ohio	93,884	$7.96M	0.0%	+0.8%	0.051%
11/15/2022	Mercer Global Advisors Inc. ADV	17,887	$1.52M	0.0%	-7.7%	0.010%
11/15/2022	Twinbeech Capital LP	161,923	$13.73M	0.4%	N/A	0.087%
11/15/2022	Two Sigma Advisers LP	396,114	$33.58M	0.1%	+54.2%	0.214%
11/15/2022	Two Sigma Investments LP	429,935	$36.45M	0.1%	+320.0%	0.232%
11/15/2022	Teza Capital Management LLC	4,162	$0.35M	0.1%	N/A	0.002%
11/15/2022	UBS Asset Management Americas Inc.	1,274,166	$108.01M	0.1%	-18.4%	0.687%
11/15/2022	Utah Retirement Systems	33,078	$2.80M	0.0%	+1.5%	0.018%
11/15/2022	Vanguard Group Inc.	17,108,289	$1.45B	0.0%	+1.6%	9.224%
11/15/2022	Perceptive Advisors LLC	336,481	$28.52M	0.8%	+86.9%	0.181%
11/15/2022	Prelude Capital Management LLC	3,612	$0.31M	0.0%	-63.1%	0.002%
11/15/2022	Price T Rowe Associates Inc. MD	611,707	$51.86M	0.0%	+16.6%	0.330%
11/15/2022	Primecap Management Co. CA	17,625,505	$1.49B	1.4%	-0.3%	9.503%
11/15/2022	Palo Alto Investors LP	1,976,265	$167.53M	13.2%	-4.1%	1.066%
11/15/2022	Paloma Partners Management Co	2,550	$0.22M	0.0%	-76.0%	0.001%
11/15/2022	Parkman Healthcare Partners LLC	42,961	$3.64M	1.0%	N/A	0.023%
11/15/2022	Pearl River Capital LLC	25,323	$2.15M	0.4%	+93.4%	0.014%
11/15/2022	Livforsakringsbolaget Skandia Omsesidigt	320	$27K	0.0%	-77.5%	0.000%
11/15/2022	Marshall Wace LLP	460,959	$39.08M	0.1%	-21.7%	0.249%
11/15/2022	Martingale Asset Management L P	83,692	$7.10M	0.1%	+7.4%	0.045%
11/15/2022	Echo Street Capital Management LLC	9,729	$0.83M	0.0%	N/A	0.005%
11/15/2022	Edgestream Partners L.P.	3,026	$0.26M	0.0%	-34.0%	0.002%
11/15/2022	Endurant Capital Management LP	145,374	$12.32M	4.0%	+459.7%	0.078%
11/15/2022	Engineers Gate Manager LP	39,677	$3.36M	0.2%	+195.8%	0.021%
11/15/2022	Ensign Peak Advisors Inc	219,572	$18.61M	0.0%	+143.1%	0.118%
11/15/2022	First Trust Advisors LP	555,293	$47.07M	0.1%	-7.2%	0.299%
11/15/2022	Frontier Capital Management Co. LLC	759,540	$64.39M	0.8%	+24.5%	0.410%
11/15/2022	First Light Asset Management LLC	123,322	$10.45M	1.1%	+17.7%	0.066%
11/15/2022	Bellevue Group AG	53,493	$4.54M	0.1%	-27.5%	0.029%
11/15/2022	Blueshift Asset Management LLC	2,523	$0.21M	0.0%	N/A	0.001%
11/15/2022	Caisse DE Depot ET Placement DU Quebec	39,783	$3.37M	0.0%	+65.8%	0.021%
11/15/2022	CI Investments Inc.	3,216	$0.27M	0.0%	+7.4%	0.002%
11/15/2022	Commonwealth Equity Services LLC	5,344	$0.45M	0.0%	-6.9%	0.003%
11/14/2022	Horizon Investments LLC	5,469	$0.46M	0.0%	N/A	0.003%
11/14/2022	AlphaCrest Capital Management LLC	16,264	$1.38M	0.1%	-30.0%	0.009%
11/14/2022	Gabelli Funds LLC	18,620	$1.58M	0.0%	+1.4%	0.010%
11/14/2022	Eaton Vance Management	61,432	$5.21M	0.0%	+0.9%	0.033%
11/14/2022	LMR Partners LLP	54,885	$4.65M	0.1%	+52.7%	0.030%
11/14/2022	Point72 Asset Management L.P.	595,400	$50.47M	0.2%	+302.6%	0.321%
11/14/2022	Cubist Systematic Strategies LLC	87,198	$7.39M	0.0%	+424.7%	0.047%
11/14/2022	Guggenheim Capital LLC	45,881	$3.89M	0.0%	-18.0%	0.025%
11/14/2022	PDT Partners LLC	11,756	$1M	0.2%	N/A	0.006%
11/14/2022	Renaissance Technologies LLC	744,471	$63.11M	0.1%	+1.3%	0.401%
11/14/2022	Cibc World Markets Corp	34,000	$2.88M	0.0%	N/A	0.018%
11/14/2022	Centiva Capital LP	32,938	$2.79M	0.1%	+9.0%	0.018%
11/14/2022	Moore Capital Management LP	53,988	$4.58M	0.1%	-27.6%	0.029%
11/14/2022	MML Investors Services LLC	5,926	$0.50M	0.0%	+2.9%	0.003%
11/14/2022	Nuveen Asset Management LLC	638,262	$54.11M	0.0%	-0.7%	0.344%
11/14/2022	Quantitative Investment Management LLC	4,309	$0.37M	0.1%	N/A	0.002%
11/14/2022	Difesa Capital Management LP	3,000	$0.25M	0.1%	+9.1%	0.002%
11/14/2022	Canada Pension Plan Investment Board	226,321	$19.19M	0.0%	+14.8%	0.122%
11/14/2022	Parkwood LLC	3,585	$0.30M	0.0%	+15.0%	0.002%
11/14/2022	Integral Health Asset Management LLC	107,000	$9.07M	1.8%	-15.3%	0.058%
11/14/2022	Healthcare of Ontario Pension Plan Trust Fund	41,000	$3.48M	0.0%	N/A	0.022%
11/14/2022	Itau Unibanco Holding S.A.	572	$48K	0.0%	-34.2%	0.000%
11/14/2022	FORA Capital LLC	8,495	$0.72M	0.1%	N/A	0.005%
11/14/2022	Royal London Asset Management Ltd.	63,902	$5.42M	0.0%	-0.4%	0.034%
11/14/2022	Shell Asset Management Co.	12,976	$1.10M	0.0%	-20.9%	0.007%
11/14/2022	Altshuler Shaham Ltd	292	$25K	0.0%	N/A	0.000%
11/14/2022	Hsbc Holdings PLC	101,080	$8.62M	0.0%	+80.1%	0.054%
11/14/2022	Prudential PLC	3,830	$0.33M	0.0%	-76.2%	0.002%
11/14/2022	E Fund Management Co. Ltd.	5,126	$0.44M	0.0%	-12.1%	0.003%
11/14/2022	Pictet Asset Management SA	768,367	$65.14M	0.1%	+56.3%	0.414%
11/14/2022	Skandinaviska Enskilda Banken AB publ	75,306	$6.38M	0.0%	-5.8%	0.041%
11/14/2022	CenterBook Partners LP	10,517	$0.89M	0.2%	+22.0%	0.006%
11/10/2022	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	18,305	$1.55M	0.0%	-13.8%	0.010%
11/10/2022	Intech Investment Management LLC	13,098	$1.11M	0.0%	-45.9%	0.007%
11/10/2022	Nomura Asset Management Co. Ltd.	103,835	$8.80M	0.1%	+5.8%	0.056%
11/10/2022	Gabelli Funds LLC	18,620	$1.58M	0.0%	+1.4%	0.010%
11/10/2022	Senator Investment Group LP	650,000	$55.10M	5.0%	-23.5%	0.350%
11/10/2022	Twin Tree Management LP	31,308	$2.65M	0.0%	+58.4%	0.017%
11/10/2022	WINTON GROUP Ltd	26,849	$2.28M	0.1%	-24.1%	0.014%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	201,385	$17.07M	0.1%	-18.5%	0.109%
11/10/2022	ExodusPoint Capital Management LP	193,816	$16.43M	0.2%	+73.9%	0.104%
11/10/2022	Dimensional Fund Advisors LP	567,934	$48.15M	0.0%	+1.3%	0.306%
11/10/2022	Wolverine Asset Management LLC	842	$71K	0.0%	-69.3%	0.000%
11/10/2022	Tower Research Capital LLC TRC	855	$73K	0.0%	-91.8%	0.000%
11/10/2022	Bank of Montreal Can	76,692	$6.60M	0.0%	-70.3%	0.041%
11/10/2022	Korea Investment CORP	79,142	$6.71M	0.0%	-26.9%	0.043%
11/10/2022	Mitsubishi UFJ Trust & Banking Corp	177,977	$15.09M	0.0%	-18.8%	0.096%
11/10/2022	Elo Mutual Pension Insurance Co	13,894	$1.18M	0.0%	-4.2%	0.007%
11/10/2022	Comgest Global Investors S.A.S.	126,415	$10.72M	0.2%	+5.5%	0.068%

Data available starting January 2016

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $103.53

$103.25

$105.34

50 Day Range

MA: $88.82

$80.93

$105.56

52 Week Range

Now: $103.53

$70.73

$106.72

Volume

985,982 shs

Average Volume

1,252,741 shs

Market Capitalization

$19.20 billion

P/E Ratio

246.50

Dividend Yield

N/A

Beta

0.37

Who are the company insiders with the largest holdings of BioMarin Pharmaceutical?: BioMarin Pharmaceutical's top insider shareholders include:
Jean Jacques Bienaime (CEO)
Richard A Meier (Director)
George Eric Davis (EVP)
Jeffrey Robert Ajer (EVP)
Michael G Grey (Director)
Charles Greg Guyer (EVP)
Brian Mueller (CFO)
V Bryan Lawlis (Director)
Mark J Alles (Director)
Dennis Slamon (Director)
Learn More about top insider investors at BioMarin Pharmaceutical.
Who are the major institutional investors of BioMarin Pharmaceutical?: BioMarin Pharmaceutical's top institutional investors include:
Primecap Management Co. CA — 9.50%
Vanguard Group Inc. — 9.22%
Barclays PLC — 1.21%
Palo Alto Investors LP — 1.07%
California Public Employees Retirement System — 0.71%
UBS Asset Management Americas Inc. — 0.69%
Learn More about top institutional investors of BioMarin Pharmaceutical stock.
Which major investors are selling BioMarin Pharmaceutical stock?: During the previous quarter, BMRN stock was sold by these institutional investors:
Allianz Asset Management GmbH
Barclays PLC
UBS Asset Management Americas Inc.
Senator Investment Group LP
Scout Investments Inc.
Bank of Montreal Can
Jennison Associates LLC
Alliancebernstein L.P.
During the previous year, company insiders that have sold BioMarin Pharmaceutical company stock include:
Jean Jacques Bienaime (CEO)
Richard A Meier (Director)
George Eric Davis (EVP)
Jeffrey Robert Ajer (EVP)
Michael G Grey (Director)
Charles Greg Guyer (EVP)
Brian Mueller (CFO)
V Bryan Lawlis (Director)
Learn More investors selling BioMarin Pharmaceutical stock.
Which major investors are buying BioMarin Pharmaceutical stock?: During the last quarter, BMRN stock was bought by institutional investors including:
Point72 Asset Management L.P.
Two Sigma Investments LP
Pictet Asset Management SA
Vanguard Group Inc.
Balyasny Asset Management LLC
Braun Stacey Associates Inc.
Twinbeech Capital LP
Nomura Holdings Inc.

Are Investors Returning to the Small-Cap Uranium Sector?

From Investing Trends | Ad

Get the Full Story on Uranium Opportunities Here

BMRN Insider Trading

BioMarin Pharmaceutical Insider Trading History Chart

BioMarin Pharmaceutical Share Price & Price History

BioMarin Pharmaceutical Insider Trading History

SEC Filings (Institutional Ownership Changes) for BioMarin Pharmaceutical (NASDAQ:BMRN)

Institutional Buying and Selling by Quarter

BioMarin Pharmaceutical Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of BioMarin Pharmaceutical?

Who are the major institutional investors of BioMarin Pharmaceutical?

Which major investors are selling BioMarin Pharmaceutical stock?

Which major investors are buying BioMarin Pharmaceutical stock?